Clinicopathologic and immunohistochemical studies of papillary thyroid microcarcinoma presenting with cervical lymphadenopathy

World Journal of Surgery

Volumn 22, Issue 7, 1998, Pages 731-737

  Sugitani, Iwao ^a   Yanagisawa, Akio ^b   Shimizu, Akira ^b   Kato, Mitsuyasu ^b   Fujimoto, Yoshihide ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; AGED; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CELL LABELING; CELL PROLIFERATION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; PROGNOSIS; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NECK; PROGNOSIS; THYROID NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031837915     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900461     Document Type: Conference Paper

References (41)

1. Sampson, R.J., Oka, H., Key, C.R., Buncher, C.R., Iijima, S.: Metastases from occult thyroid carcinoma: an autopsy study from Hiroshima and Nagasaki, Japan. Cancer 25:803, 1970
2. Sampson, R.J., Key, C.R., Buncher, C.R., Oka, H.,Iijima, S.: Papillary carcinoma of the thyroid gland: sizes of 525 tumors found at autopsy in Hiroshima and Nagasaki. Cancer 25:1391, 1970
3. Sampson, R.J., Woolner, L.B., Bahn, R.C., Kurland, L.T.: Occult thyroid carcinoma in Olmsted Country, Minnesota: prevalence at autopsy compared with that in Hiroshima and Nagasaki, Japan. Cancer 34:2012, 1974
4. Fukunaga, F.H., Yatani, R.: Geographic pathology of occult thyroid carcinomas. Cancer 36:1095, 1975
5. Bondeson, L., Ljungberg, O.: Occult thyroid carcinoma at autopsy in Malmö, Sweden. Cancer 47:319, 1981
6. Woolner, L.B., Lemmon, M.L., Beahrs, O.H., Black, B.M., Keating, F.R., Jr.: Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. J. Clin. Endocrinol. Metab. 20:89, 1960
7. Hubert, J.P., Jr., Kiernan, P.D., Beahrs, O.H., McConahey, W.M., Woolner, L.B.: Occult papillary carcinoma of the thyroid. Arch. Surg. 115:394, 1980
8. Cady, B.: Surgery of thyroid cancer. World J. Surg. 5:3, 1981
9. McConahey, W.M.: Thyroidology: past, present and future. In: Common Problems in Endocrine Surgery. J.A. van Heerden. editor. Chicago, Year Book, 1989, pp. 132-140
10. Aiyoshi, Y., Ishikawa, T., Morishima, I., Yashiro, T., Hara H., Nakamura, Y., Yamashita, K.: Regional lymph node metastases from differentiated thyroid carcinomas smaller than 1 cm. Endocr. Surg. 12:43, 1995
11. Yamashita, H., Noguchi, S., Murakami, N., Mochizuki, Y., Nakayama, I.: Prognosis of minute carcinoma of thyroid: follow-up study of 49 patients. Acta Pathol. Jpn. 36:1469, 1986
12. Strate, M., Lee, E.L., Childers, J.H.: Occult papillary carcinoma of the thyroid with distant metastases. Cancer 54:1093, 1984
13. Allo, M.D., Christianson, W., Koivunen, D.: Not all "occult" papillary carcinomas are "minimal." Surgery 104:971, 1988
14. Sanders, L.E., Rossi, R.L.: Occult well differentiated thyroid carcinoma presenting as cervical node disease. World J. Surg. 19:642, 1995
15. Cady, B., Rossi, R.L.: An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 104:947, 1988
16. Hazard, J.B.: Small papillary carcinoma of thyroid: a study with special reference to so-called nonencapsulated sclerosing tumor. Lab. Invest. 9:86, 1960
17. Iida, F., Sugenoya, A., Muramatsu, A.: Clinical and pathologic properties of small differentiated carcinomas of the thyroid gland. World J. Surg. 15:515. 1991
18. Hedinger, C., Williams, E.D., Sobin, L.H.: Histologic typing of thyroid tumors. In: International Histological Classification of Tumors, World Health Organization (2nd ed., no. 11) New York, Springer, 1988, pp. 9-10
19. Olofsson, A., Miyazono, K., Kanzaki, T., Colosetti, P., Engström, U., Heldin, C-H.: Transforming growth factor-β1, -β2, and -β3 secreted by a human glioblastoma cell line: identification of small and different forms of large latent complexes. J. Biol. Chem. 267:19482, 1992
20. Hay, I.D., Grant, C.S., van Heerden, J.A., Goellner, J.R., Ebersold, J.R., Bergstralh, E.J.: Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112:1139, 1992
21. Noguchi, S., Noguchi, A., Murakami, N.: Papillary carcinoma of the thyroid. I. Developing pattern of metastasis. Cancer 26:1053, 1970
22. Henry, J-F., Denizot, A., Bellus, J-F., Bordigoni, L., Niccoli, P., De Micco, C.: Papillary thyroid carcinomas revealed by metastatic cervical lymph nodes. Endocr. Surg. 9:349, 1992
23. Harris, C.C., Hollstein, M.: Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329:1318, 1993
24. Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., Pierotti, M.A.: p53 mutations are restrcted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 91:1753, 1993
25. Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T., Dohi, K., Nakamura, N., Akiyama, M.: Genetic alterations in thyroid tumor prigression: association with p53 gene mutations. Jpn. J. Cancer Res. 84:526, 1993
26. Dobashi, Y., Sugimura, H., Sakamoto, A., Mernyei, M., Mori, M., Oyama, T., Machinami, R.: Stepwise participation of p53 gene mutation during dedifferentiation of human thyroid carcinomas. Diagn. Mol. Pathol. 3:9, 1994
27. Nishida, T., Nakao, K., Hamaji, M., Nakahara, M., Tsujimoto, M.: Overexpression of p53 protein and DNA content are important biologic prognostic factors for thyroid cancer. Surgery 119:568, 1996
28. Gerdes, J., Schwab, U., Lemke, H., Stein, H.: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 31:13, 1983
29. Brown, D.C., Gatter, K.C.: Monoclonal antibody Ki-67: its use in histopathology; invited review. Histopathology 17:489, 1990
30. Roberts, A.B., Sporn, M.B.: The transforming growth factor-βs. In: Peptide Growth Factors and Their Receptors (vol. 1). New York, Springer, 1991, pp. 419-472
31. Hölting, T., Zielke, A., Siperstein, A.E., Clark, O.H., Duh, Q-Y.: Transforming growth factor-β1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J. Clin. Endocrinol. Metab. 79:806, 1994
32. Sanford, L.P., Ormsby, I., Gittenberger-de Groot, A.C., Sariola, H., Friedman, R., Boivin, O.P., Cardell, E.L., Doetschman, T.: TGFβ2 knockout mice have multiple developmental defects that are non-overlapping with other TGFβ knockout phenotypes. Development 124:2659, 1997
33. Massagué, J., Attisano, L., Wrana, J.L.: The TGF-β family and its composite receptors. Trends Cell Biol. 4:172, 1994
34. Miyazono, K., ten Dijke, P., Yamashita, H., Heldin, C-H.: Signal transduction via serine/threonine kinase receptors. Cell Biol. 5:389, 1994
35. Jasani, B., Wyllie, F.S., Wright, P.A., Lemoine, N.R., Williams, E.D., Wynford-Thomas, D.: Immunocytochemically detectable TGF-β associated with malignancy in thyroid epithelial neoplasia. Growth Factors 2:149, 1990
36. Mizoi, T., Ohtani, H., Miyazono, K., Miyazawa, M., Matsuno, S., Nagura, H.: Immunoelectron microscopic localization of transforming growth factor-β1 and latent transforming growth factor-β1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells. Cancer Res. 53:183, 1993
37. Markowitz, S., Wang, J., Myeroff, L., Parsons, R., Sun, L., Lutterbaugh, J., Fan, R.S., Zborowska, E., Kintzer, K.W., Vogelstein, B., Brattain, M., Willson, J.K.V.: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268:1336, 1995
38. Eppert, K., Scherer, S.W., Ozcelik, H., Pirone, R., Hoodless, P., Kim, H., Tsui, L-C., Bapat, B., Gallinger, S., Andrulis, I.L., Thomsen, G.H., Wrana, J.L., Attisano, L.: MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543, 1996
39. Hahn, S.A., Schutte, M., Shamsul Hoque, A.T.M., Moskaluk, C.A., da Costa, L.T., Rozenblum, E., Weinstein, C.L., Fisher, A., Yeo, C.J., Hruban, R.H., Kern, S.E.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350, 1996
40. Nagatake, M., Takagi, Y., Osada, H., Uchida, K., Mitsudomi, T., Saji, S., Shimokata, K., Takahashi, T., Takahashi, T.: Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:2718, 1996
41. Yi Kim, I., Ahn, H-J., Zelner, D.J., Shaw, J.W., Lang, S., Kato, M., Oefelein, M.G., Miyazono, K., Nemeth, J.A., Kozlowski, J.M., Lee, C.: Loss of expression of transforming growth factor-β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin. Cancer Res. 2:1255, 1996